Here are five updates on GI companies from the past week:
The FDA approved Pentax's ED34-i10T, a duodenoscope with a disposable, single-use distal cap.
Allergan's board of directors authorized the company to buy back $2 billion in stock, while also committing to increasing its quarterly dividends and reaffirming its decision to pay down $3.75 billion in debt by 2018.
The FDA approved Bracco Diagnostics' Tagitol V oral suspension for adult patients undergoing virtual colonoscopy.
A study from England-based Oxford University further validated Medial EarlySign's ColonFlag.
Landos Biopharma completed a series A financing round raising $10 million.